UCB ( UCB)

Primary tabs

UCB's picture

Management

??

Contact Address

Brussels, Belgium

About UCB

UCB (Union Chimique Belge) is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with a revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's, and Crohn's diseases.[3] The Company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system (CNS) disorders (including epilepsy), inflammatory disorders (including allergy), and oncology.

UCB press release, blog etc

Tue, 05/20/2025 - 08:39 UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences
Tue, 04/01/2025 - 01:23 UCB presents key data from Alzheimers and Parkinsons disease research programs at AD/PD 2025
Fri, 03/07/2025 - 14:10 Share Repurchase Program 2025 to cover UCB's Long Term Incentive Plans for employees
Wed, 01/15/2025 - 01:15 UCB showcases decade of growth and Patient Value Strategy driving differentiated innovation
Sat, 01/11/2025 - 02:46 UCB partners with Ailux Biologics, a Division of XtalPi, on Biologics AI Platform
Tue, 12/17/2024 - 01:45 Findings from minzasolmin proof-of-concept ORCHESTRA study shape next steps in UCB Parkinsons research program
Tue, 06/11/2024 - 20:51 Global experts release new guidelines on prevention of progression of epileptic seizures, addressing critical treatment gaps
Mon, 03/04/2024 - 22:31 UCB announces strategic investment in IMIDomics, Inc to advance breakthrough solutions for immune-mediated inflammatory diseases
Tue, 12/13/2022 - 18:12 UCB and Praxis Precision Medicines Announce Epilepsy Research Collaboration
Tue, 11/22/2022 - 13:50 UCB Submits Response to FDA Complete Response Letter for Bimekizumab
Fri, 07/01/2022 - 15:42 Acquisition and disposal of own shares
Fri, 03/18/2022 - 16:37 Transparency notification FMR LLC
Tue, 11/30/2021 - 16:49 UCB and Chiesi enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases
Wed, 10/20/2021 - 03:53 UCB to license its AI technology that improves identification of Osteoporosis to ImageBiopsy Lab
Tue, 05/04/2021 - 02:49 UCB's General Meeting of Shareholders 2021
Wed, 04/28/2021 - 04:04 UCB Announces PDUFA Date for Bimekizumab
Wed, 04/14/2021 - 02:41 Notice of Early Redemption - 350 million 1.875% fixed rate notes due
Wed, 03/24/2021 - 02:44 Transparency notification UCB SA/NV
more

InfoBox

Formation1928
HeadChristophe Tellier
FounderEmmanuel Janssen
Employees7489
LocationBrussels
HomePagewww.ucb.com
Facebookwww.facebook.com/UCBBiopharma
Twitterwww.twitter.com/ucb_news
YouTubewww.youtube.com/UCB
Instagramwww.instagram.com/ucb_biopharma
LinkedInwww.linkedin.com/company/ucb-pharma
Wikipediaen.wikipedia.org/wiki/UCB_(company)